Laurent Brard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7212123/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of Somatic Mitochondrial DNA Mutations, Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three Endometrial Cancer Patients. Life, 2022, 12, 562.	1.1	2
2	Assessment of the diagnostic and prognostic relevance of ACAT1 and CE levels in plasma, peritoneal fluid and tumor tissue of epithelial ovarian cancer patients - a pilot study. BMC Cancer, 2022, 22, 387.	1.1	6
3	Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer. PLoS ONE, 2020, 15, e0227707.	1.1	28
4	Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression—An in vitro study. PLoS ONE, 2020, 15, e0228024.	1.1	31
5	Rural–urban differences in surgical treatment, regional lymph node examination, and survival in endometrial cancer patients. Cancer Causes and Control, 2018, 29, 221-232.	0.8	13
6	Utility and Generalizability of Multistate, Population-Based Cancer Registry Data for Rural Cancer Surveillance Research in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1252-1260.	1.1	18
7	Rural–Urban Differences in Cancer Incidence and Trends in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1265-1274.	1.1	264
8	Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer, 2017, 17, 49.	1.1	19
9	Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines. PLoS ONE, 2017, 12, e0185111.	1.1	9
10	Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. Anti-Cancer Drugs, 2016, 27, 547-559.	0.7	6
11	Expression Profiling of Primary and Metastatic Ovarian Tumors Reveals Differences Indicative of Aggressive Disease. PLoS ONE, 2014, 9, e94476.	1.1	66
12	Bithionol inhibits ovarian cancer cell growth In Vitro- studies on mechanism(s) of action. BMC Cancer, 2014, 14, 61.	1.1	38
13	PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Genes and Cancer, 2013, 4, 524-534.	0.6	11
14	Identification of Ovarian Cancer Metastatic miRNAs. PLoS ONE, 2013, 8, e58226.	1.1	78
15	Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. International Journal of Oncology, 2012, 40, 227-35.	1.4	34
16	Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. International Journal of Oncology, 2012, 40, 99-108.	1.4	21
17	WNT7A Regulates Tumor Growth and Progression in Ovarian Cancer through the WNT/β-Catenin Pathway. Molecular Cancer Research, 2012, 10, 469-482.	1.5	159
18	Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C. BMC Cancer, 2012, 12, 147	1.1	30

LAURENT BRARD

#	Article	IF	CITATIONS
19	Cytotoxic Properties of Adamantyl Isothiocyanate and Potential <i>In vivo</i> Metabolite Adamantylâ€ <i>N</i> â€Acetylcystein in Gynecological Cancer Cells. Chemical Biology and Drug Design, 2012, 79, 92-103.	1.5	2
20	7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. Gynecologic Oncology, 2012, 126, 252-258.	0.6	9
21	Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model. PLoS ONE, 2012, 7, e34443.	1.1	16
22	Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. International Journal of Oncology, 2011, 38, 1329-41.	1.4	18
23	Organometallic Iron(III)-Salophene Exerts Cytotoxic Properties in Neuroblastoma Cells via MAPK Activation and ROS Generation. PLoS ONE, 2011, 6, e19049.	1.1	17
24	A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2011, 33, 25-30.	0.3	41
25	T090137 Inhibits Cisplatin-Induced Apoptosis in Ovarian Cancer Cells. International Journal of Gynecological Cancer, 2011, 21, 1350-1356.	1.2	8
26	Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecologic Oncology, 2011, 122, 183-189.	0.6	23
27	Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. Gynecologic Oncology, 2011, 123, 370-378.	0.6	11
28	A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells. Investigational New Drugs, 2011, 29, 63-72.	1.2	49
29	Integrated genomics of ovarian xenograft tumor progression and chemotherapy response. BMC Cancer, 2011, 11, 308.	1.1	10
30	Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro. Cancer Biology and Therapy, 2011, 11, 1036-1045.	1.5	8
31	Effect of a Vitamin D3 derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Investigational New Drugs, 2010, 28, 543-553.	1.2	17
32	Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. BMC Cancer, 2010, 10, 72.	1.1	13
33	Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model. Chemical Biology and Drug Design, 2010, 76, 164-173.	1.5	7
34	Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model. Drug Design, Development and Therapy, 2009, 3, 17.	2.0	9
35	Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?. International Journal of Gynecological Cancer, 2009, 19, 343-347.	1.2	4
36	Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinumâ€resistant ovarian cancer cells to paraplatin. Phytotherapy Research, 2009, 23, 1066-1074.	2.8	56

LAURENT BRARD

#	Article	IF	CITATIONS
37	Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo. Journal of Pediatric Hematology/Oncology, 2009, 31, 187-193.	0.3	36
38	Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Design, Development and Therapy, 2009, 2, 61-9.	2.0	7
39	Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells. British Journal of Cancer, 2008, 99, 1823-1831.	2.9	13
40	Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial. Gynecologic Oncology, 2008, 109, 65-70.	0.6	62
41	A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells. Gynecologic Oncology, 2008, 109, 240-249.	0.6	19
42	Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines. Letters in Organic Chemistry, 2008, 5, 103-109.	0.2	3
43	For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 39-42.	0.6	11
44	Iron(III)-Salophene: An Organometallic Compound with Selective Cytotoxic and Anti-Proliferative Properties in Platinum-Resistant Ovarian Cancer Cells. PLoS ONE, 2008, 3, e2303.	1.1	50
45	Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5846-5852.	1.0	27
46	Antiâ€proliferative and Proâ€apoptotic Properties of 3â€Bromoacetoxy Calcidiol in Highâ€risk Neuroblastoma. Chemical Biology and Drug Design, 2007, 70, 302-310.	1.5	21
47	Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecologic Oncology, 2007, 105, 81-83.	0.6	55
48	Inguinal Sentinel Node Dissection versus Standard Inguinal Node Dissection in Patients With Vulvar Cancer: A Comparison of the Size of Metastasis Detected in Inguinal Lymph Nodes. Obstetrical and Gynecological Survey, 2006, 61, 518-519.	0.2	2
49	Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf. Angiogenesis, 2006, 8, 349-360.	3.7	36
50	Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecologic Oncology, 2006, 100, 116-127.	0.6	53
51	Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. Gynecologic Oncology, 2006, 101, 24-27.	0.6	27
52	The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecologic Oncology, 2006, 103, 176-180.	0.6	87
53	Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. Gynecologic Oncology, 2006, 103, 261-270.	0.6	115
54	Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro. Journal of Experimental Therapeutics and Oncology, 2006, 5, 287-300.	0.5	34